Among the grants approved by the Board recently were four TB grants and one TB/HIV grant to India. In this article, we report on the comments from the Technical Review Panel (TRP) and the Grants Approvals Committee (GAC) on the funding request from which these grants emanated.
The Global Fund’s Fifth Replenishment Conference in Montreal involved much more than just donors making their formal pledges for the next three years.
The Global Fund’s replenishment campaign cranked up a notch in May with the announcement by Prime Minister Shinzo Abe of Japan of a USD 800 million pledge to The Global Fund’s Fifth Replenishment ahead of G7 Summit which was held on 26–27 May in Japan.
The European Commission is pledging € 470 million to The Global Fund for 2017-2019, an increase of € 100 million, or 27%, over the EC’s pledge for 2014-2016.
Papua New Guinea has signed a $14.2 million grant with the Global Fund under the new funding model that emphasizes outreach and targeted prevention messages for key populations, as well as continuing service delivery even to the most remote areas in the Pacific nation.
Mozambique, where malaria is nationally endemic and still a major driver of mortality especially among children, is a good example of how collaboration between government, civil society and the private sector can contribute to an effective response to the disease.
by Njihia Mbitiru
The Global Fund is participating in an initiative to leverage private sector funding to speed up delivery of, and expand access to, health products such as contraceptives, bed nets and medicines. The initiative is called the “Pledge Guarantee for Health.”
The Global Fund has developed new minimum standards for implementers. Entities covered by the standards include principal recipients (PRs), large sub-recipients (SRs) and other associated actors, such as public- or private-sector entities involved in the pharmaceutical and health products procurement and supply chain, as well as components of the national health system.
The future of the Affordable Medicines Facility–malaria (AMFm) will be decided at the Global Fund Board meeting on 14–15 November 2012. The outcome appears anything but certain. The AMFm was launched as a two-year pilot phase in April 2009 and began operations in July 2010. The AMFm is hosted by the Global Fund but its programme funding comes from other donors.